



LETTER TO THE EDITOR

The benefit of macrolide therapy in patients with pneumococcal pneumonia is only present in patients with bacteremia

Dear Editor

Community acquired pneumonia (CAP) remains the deadliest infectious disease worldwide, especially at the extremes of life and *Streptococcus pneumoniae* continues to be its most important pathogen.¹ The role of combination antibiotic therapy with a macrolide in patients with *Streptococcus pneumoniae* severe pneumonia, admitted to hospital, although commonly recommended, is still controversial. Identification of patients who might benefit from this strategy is crucial to maximize its benefit whilst reducing antimicrobial overuse, bacterial resistance pressure and toxicity. Positive effects have been previously reported in patients with invasive mechanical ventilation,² severe CAP³ and with bacteremia,⁴ although these studies have been carried out in the intensive care unit (ICU) population and the same benefit may not apply to the general population. Moreover, as the population admitted to the hospital is also changing (patients are commonly older and often present comorbidities), this deserves further clarification.

We performed a multicenter study addressing the outcomes of patients admitted with *Streptococcus pneumoniae* CAP. The study protocol was approved by the Hospital Vila Franca de Xira Ethical Committee at their 25-1-2019 meeting. Informed consent was waived due to the retrospective, observational only, nature of the study. All Ethical Committee of participating centers approved the submitted protocol.

We included 797 adult patients (53.4% male, mean age 72.4±16.5 years, 92.5% with at least one comorbidity) admitted to one of the 4 participating centers, between 2015 and 2018, with microbiological documented *Streptococcus pneumoniae* (either bacteremia or urinary antigen) CAP. Bacteremia was defined as a clinical and radiological syndrome consistent with pneumonia and ≥1 blood culture(s) positive for *Streptococcus pneumoniae*.

ICU admission was recorded in 18.8%. Demographic and clinical data, along with antimicrobial therapy, were collected. Outcome data included length of hospital stay, 30-day and 1-

year all-cause mortality. Patients were split according to the presence of pneumococcal bacteremia (N=240, 30.1%). Their characteristics are presented in Table 1.

Cox proportional Hazards (HR), along with the 95% CI, was used for assessment of combination antimicrobial therapy with a macrolide, for patients with and without bacteremia.

Mean hospital length of stay was 11.7±9.8 days. The overall 30-day all-cause mortality was 19.2% (32.2% at 1-year follow-up). Patients with bacteremia had higher 30-day all-cause mortality (26.2% vs. 16.3%, age adjusted Hazards Ratio [aHR] 1.84; 95% CI 1.33-2.53) and 1-year all-cause mortality (38.5% vs. 30.4%, aHR 1.43; 95% CI 1.05-1.96). Combination of a β-lactam plus a macrolide was given to 459 patients (57.6%), 57.1% of those with bacteremia and 57.8% of those without (p=0.88). This proved to be beneficial but only for patients with bacteremia (30-day all-cause mortality 18.8% vs. 36.1%, aHR 0.49 95% CI 0.30-0.80, p=0.004) - Fig. 1. After 1-year of follow up, patients with bacteremia, who received combination antimicrobial therapy with a macrolide, still had lower all-cause mortality, 31.3% vs. 48.1%, p=0.009.

The benefit of combination antimicrobial therapy with a macrolide in patients with bacteremia was also found in a large 2007 retrospective study,⁵ even in patients who received only 24h of a macrolide.⁵ However, this study failed to provide a control group. The same benefit, improved survival of patients with pneumococcal bacteremia with combination antimicrobial therapy, was noted in another small study, but only in the most severe group. However, the population included was younger and healthier than ours, with an all-cause mortality rate of only 16.9%.⁴

The reasons for the benefit of macrolides may be related to its non-antibiotic properties, namely a potential “immunomodulatory” effect, although this needs further clarification.⁶ Persistent inflammation probably plays a contributing role in a worst short- and long-term prognosis in patients with CAP,⁷ especially related with an increased incidence of cardiovascular diseases. In our cohort 18.3% of patients discharged alive from the hospital died during the 1-year of follow-up, slightly higher than previously reported.⁸ It should be noted that our population was older (71±16.8 vs. 63 years old) and age is a well-known risk factor for long term mortality.

Our study has some limitations. It is retrospective and included all hospitalized patients diagnosed with

<https://doi.org/10.1016/j.pulmoe.2022.08.003>

2531-0437/© 2022 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article in press as: J. Gonçalves-Pereira, L. Costa, I. Silva et al., The benefit of macrolide therapy in patients with pneumococcal pneumonia is only present in patients with bacteremia, Pulmonology (2022), <https://doi.org/10.1016/j.pulmoe.2022.08.003>

Table 1 Characteristics of subjects with or without bacteremia.

	Bacteriemia	No	Odds Ratio (95% CI)	P Value
Age (years)	71.3±15.8	72.9±16.8		0.195*
Time of symptoms before admission (days)	2 [1-4.3]	3 [1-5]		0.037‡
CRP max (mg/dL)	29.3±12.3	21.5±11.8		<0.001*
Diabetes	28.2	26.5	1.09 [0.78-1.53]	0.667†
Hypertension	44.4	48.8	0.84 [0.62-1.14]	0.283†
Smoking	17.5	18.5	0.93 [0.63-1.38]	0.766†
COPD	15.5	18.1	0.83 [0.55-1.24]	0.418†
Atrial Fibrillation	24.2	17.6	1.50 [1.04-2.16]	0.034†
Cachexia	4.8	5.9	0.80 [0.41-1.60]	0.616†
Malignant Neoplasm	9.1	7.6	1.23 [0.72-2.1]	0.483†
ICU admission	27.0	15.3	2.04 [1.42-2.95]	<0.001†
IMV	9.1	15.7	1.67 [0.95-2.93]	0.093†
NIMV	15.1	10.6	1.50 [0.96-2.33]	0.078†
RRT	13.5	12.1	1.13 [0.72-1.76]	0.644†
Multilobar involvement	39.0	38.3	1.03 [0.76-1.41]	0.875†
Sepsis	45.8	50.4	0.832 [0.62-1.13]	0.248†
Hospital length of stay (days)	13.8±11.9	10.8±8.5		<0.001*
Hospital mortality	26.6	14.0	2.23 [1.54-3.23]	<0.001†
30-day mortality	26.2	16.3	1.83 [1.27-2.63]	0.001†
1-Year mortality	38.5	30.4	1.43 [1.05-1.96]	0.028†

Data presented as %, unless otherwise stated; Continuous variables are presented as mean ± standard deviation or median [interquartile range] according to data distribution; CRP - C reactive protein; COPD – Chronic obstructive pulmonary disease; IMV – Invasive mechanical ventilation; NIMV – Non invasive mechanical ventilation; RRT – Renal Replacement therapy.

* Student' T Test.

† Chi-Square Test.

‡ Mann Whitney U test.

Streptococcus pneumoniae CAP. However, there was no systematic patient assessment on admission, and a significant number may have been missed. Moreover, although collection of blood cultures is common practice in patients with CAP who require hospital admission, previous use of antimicrobials or failure to collect blood while still in the emergency department may have contributed to a misclassification. Also, our database included only patients admitted to the hospital between 2015 and 2018, before the SARS-CoV2 pandemic. However, we believe that no significant changes have been made to the approach to patients with pneumococcal CAP.⁹ Finally, we did not collect all patient' clinical and laboratory data on hospital admission and severity imbalances between groups may have occurred.

In conclusion we presented a large cohort of patients with pneumococcal CAP. Isolation of *Streptococcus pneumoniae* bacteremia was associated with high 30-day and 1-year all-cause mortality. On the other hand, patients with bacteremia who received combination antimicrobial therapy with a macrolide had lower 30-day mortality, but this benefit was not found in those with negative blood cultures.

Financial support

This work was supported by a research grant from Merck Sharp & Dohme Corp., a division of Merck & Co., Inc.,

Kenilworth, NJ, USA [IIS# 60150] under the Investigator Studies Program.

The content of this publication reflects only the views of the authors. The sponsor had no role in the analyses or interpretation of the data.

Authors contributions

João Gonçalves Pereira acts as guarantor of the integrity and accuracy of the data.

JGP, DL, PM, FF designed the study; AS, PVR, LC, RA, IS, MC, PM acquired the data and performed literature search; JGP, AG check the data for missing or implausible values; JGP, PM, IS, DL, AG analyse and interpret the data; JGP, PM, FF drafted the manuscript; JGP, AS, AG, PM, FF, DL revised the manuscript for important intellectual content; JGP, AG provided the statistical expertise. All authors review and approved the final manuscript.

Conflicts of interest

JGP reported he had received an unrestricted grant from Merck Sharp and Dohme; Consulting fees from Pfizer pharmaceuticals, Biomerieux and AOP pharmaceuticals; Honoraria for lectures from Abionic and Pfizer pharmaceuticals; and honoraria for participating in an advisory board from




Fig. 1 A 30-day Mortality benefit was found in patients who received combination antimicrobial therapy with a macrolide but only in those with pneumococcal bacteremia (panel A); No differences were found in those without bacteremia (panel B): Age adjusted hazards ratio 0.49; 95% CI 0.30-0.80 and 0.94; 95% CI 0.64-1.51, respectively.

Pfizer Pharmaceutical. He is currently the president of “Grupo de Investigação e Desenvolvimento em Sepsis”. FF reported he had received honoraria for lectures from Merck Sharp and Dohme, Pfizer pharmaceuticals and Sanofi; support for attending meetings from Merck Sharp and Dohme, Pfizer pharmaceuticals and Sanofi; and honoraria for participating in advisory boards from Merck Sharp and Dohme, Pfizer pharmaceuticals and Sanofi. PM reported he had received unrestricted grant from Merck Sharp and Dohme

and Astra Zeneca; Consulting fees from Glaxo, Smith, Kline pharmaceuticals, Biomerieux, Astra Zeneca, Merck Sharp and Dohme and Shinogi; Honoraria for lectures from Cepheid, Glaxo Smith Kline, Merck Sharp and Dohme, Octapharma and Pfizer pharmaceuticals; support for attending meetings from Merck Sharp and Dohme. He is currently the president of the Portuguese National Society of Intensive Care. The other authors have nothing to disclose.

References

1. Feldman C, Anderson R. The role of streptococcus pneumoniae in community-acquired pneumonia. *Semin Respir Crit Care Med.* 2020;41:455–69. <https://doi.org/10.1055/s-0040-1702193>.
2. Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. *Intensive Care Med.* 2010;36:612–20. <https://doi.org/10.1007/s00134-009-1730-y>.
3. Pereira JM, Gonçalves-Pereira J, Ribeiro O, Baptista JP, Froes F, Paiva JA. Impact of antibiotic therapy in severe community-acquired pneumonia: data from the Infauci study. *J Crit Care.* 2018;43:183–9. <https://doi.org/10.1016/j.jcrc.2017.08.048>.
4. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. *Am J Respir Crit Care Med.* 2004;170:440–4. <https://doi.org/10.1164/rccm.200311-1578OC>.
5. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. *Chest.* 2007;131:466–73. <https://doi.org/10.1378/chest.06-1426>.
6. Reijnders TDY, Saris A, Schultz MJ, van der Poll T. Immunomodulation by macrolides: therapeutic potential for critical care. *Lancet Respir Med.* 2020;8:619–30. [https://doi.org/10.1016/S2213-2600\(20\)30080-1](https://doi.org/10.1016/S2213-2600(20)30080-1).
7. Steel HC, Cockeran R, Anderson R, Feldman C. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. *Mediators Inflamm.* 2013. <https://doi.org/10.1155/2013/490346>. 2013.
8. Sandvall B, Rueda AM, Musher DM. Long-term survival following pneumococcal pneumonia. *Clin Infect Dis.* 2013;56:1145–6. <https://doi.org/10.1093/cid/cis1207>.
9. Garber B. Pneumonia update for emergency clinicians. *Curr Emerg Hosp Med Rep.* 2022;10:36–44. <https://doi.org/10.1007/s40138-022-00246-z>.

J. Gonçalves-Pereira^{a,b,c,*}, L. Costa^d, I. Silva^e, A. Simões^a, F. Froes^{f,g}, P. Mergulhão^{c,h,i}, P. Varela Ramos^a, D. Leal^d, R. Alves^d, M. Custódio^e, A. Gomes^{c,e,i}

^a Intensive Care Department, Hospital Vila Franca de Xira; Vila Franca de Xira, Portugal

^b Nova Medical School, Universidade Nova de Lisboa, Lisbon, Portugal

^c Grupo de Infeção e Desenvolvimento em Sépsis, Oporto, Portugal

^d Intensive Care Department, Hospital Braga; Braga, Portugal

^e Internal Medicine Department, Hospital Cascais; Cascais, Portugal

^f Intensive Care Department, Centro Hospitalar S. João, Oporto, Portugal

^g Chest Department, Hospital Pulido Valente, Centro Hospitalar Lisboa Norte, Lisbon, Portugal

^h Intensive Care Unit, Hospital Lusíadas, Oporto, Portugal

ⁱ Faculdade de Medicina, Universidade do Porto, Oporto, Portugal

* Corresponding author at: Intensive Care Unit, Hospital Vila Franca de Xira, Estrada Carlos Lima Costa, N2, 2600-009 Vila Franca de Xira, Portugal.

E-mail address: joao.goncalvespereira@hvf.min-saude.pt (J. Gonçalves-Pereira).

Received 25 July 2022; Accepted 5 August 2022

Available online xxx